Literature DB >> 24000252

Tiotropium Respimat increases the risk of mortality: con.

Eric D Bateman.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24000252     DOI： 10.1183/09031936.00042213

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  7 in total

Review 1.  Advances in device and formulation technologies for pulmonary drug delivery.

Authors:  John Gar Yan Chan; Jennifer Wong; Qi Tony Zhou; Sharon Shui Yee Leung; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2014-04-12       Impact factor: 3.246

Review 2.  Tiotropium Respimat®: A Review of Its Use in Asthma Poorly Controlled with Inhaled Corticosteroids and Long-Acting β2-Adrenergic Agonists.

Authors:  Kate McKeage
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

Review 3.  Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

4.  Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.

Authors:  Francesco Trotta; Roberto Da Cas; Maja Rajevic; Mariangela Rossi; Giuseppe Traversa
Journal:  BMJ Open       Date:  2015-05-25       Impact factor: 2.692

5.  Inhaled bronchodilators and acute myocardial infarction: a nested case-control study.

Authors:  Chang-Hoon Lee; Seongmi Choi; Eun Jin Jang; Han-Mo Yang; Ho Il Yoon; Yun Jung Kim; Jimin Kim; Jae-Joon Yim; Deog Kyeom Kim
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

Review 6.  Tiotropium in chronic obstructive pulmonary disease - a review of clinical development.

Authors:  Antonio Anzueto; Marc Miravitlles
Journal:  Respir Res       Date:  2020-07-29

7.  Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study.

Authors:  Francesco Trotta; Stefania Spila-Alegiani; Roberto Da Cas; Maja Rajevic; Valentino Conti; Mauro Venegoni; Mariangela Rossi; Giuseppe Traversa
Journal:  PLoS One       Date:  2017-04-21       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.